NextCure stock soared 45% in after-hours trading as its preclinical antibody NC605 showed strong results for brittle bone disease. In mouse models, it boosted bone density, reduced fractures, and outperformed anti-sclerostin. With no FDA-approved treatment for OI, analysts see NC605 as a potential game-changer for patients.